Table 1

Demographics and clinical features of 55 aPL-positive patients with first observed pregnancies after the registry recruitment, by composite pregnancy morbidity (preterm live delivery at or before 37th week due to pre-eclampsia, small-for-gestational age, and/or placental insufficiency, or otherwise unexplained fetal death after the 10th week of gestation)

N (%)Composite pregnancy morbidity
(N: 9)
No composite pregnancy morbidity
(N: 46)
Demographics*
 Race
  White (n:33)4 (12%)29 (88%)
  Latin American (n:9)09 (100%)
  Asian (n:8)3 (38%)5 (63%)
  Black (n:1)1 (100%)0
 Mean age at registry entry (years, mean±SD): 31.5±5.430±5.931.9±5.2
 Mean maternal age (years, mean±SD): 33.4±5.232.2±5.733.7±5.1
Systemic autoimmune disease diagnosis
 Primary APS† (n:31)5 (16%)26 (84%)
 APS† with SLE (n:9)1 (11%)8 (89%)
 Primary aPL-positivity (no APS) (n:10)1 (10%)9 (90%)
 aPL-positivity (no APS) with SLE (n:5)2 (40%)3 (60%)
aPL/APS† Classification
 Thrombotic and obstetrical APS† (n:14)1 (7%)13 (93%)
 Thrombotic APS† (n:18)4 (22%)14 (78%)
 Obstetrical APS† (n:8)1 (13%)7 (88%)
 aPL without APS† (n:15)3 (20%)12 (80%)
Clinical characteristics
 History of arterial thrombosis, venous thrombosis or
 microthrombosis (n:32)
5 (16%)27 (84%)
  1 Event (n:18)2 (11%)16 (89%)
  2 Events (n:10)3 (30%)7 (70%)
  3 Events and more (n:4)04 (100%)
 History of pregnancy (n:38)4 (11%)34 (89%)
  Pregnancy morbidity (n:30)4 (13%)26 (87%)
  No pregnancy morbidity (n:8)08 (100%)
 Non-criteria manifestations
  Thrombocytopenia (n:14)4 (29%)10 (71%)
  Livedo reticularis (n:6)1 (17%)5 (83%)
  White matter lesions (n:3)1 (33%)2 (67%)
  Autoimmune haemolytic anaemia (n:2)1 (50%)1 (50%)
  Cardiac valve disease (n:3)1 (33%)2 (67%)
  aPL-nephropathy (n:1)1 (100%)0
Laboratory characteristics
 Triple aPL-positive (n:18)3 (17%)15 (83%)
 LA-positive alone‡ (n:17):4 (24%)13 (76%)
 Double aPL-positive (n:17)2 (12%)15 (88%)
 LA+aCL (n:13)2 (15%)11 (85%)
 aCL+aβ2GPI (n:2)02 (100%)
 LA+aβ2GPI (n:2)02 (100%)
  • *Eighteen of 55 were recruited from North America, 11 South America, 19 Europe and 7 Asia.

  • †APS based on the updated Sapporo classification criteria1

  • ‡aCL and aβ2GPI not tested in two pregnancies; aβ2GPI not tested in three pregnancies.

  • aCL, anticardiolipin antibody; aPL, antiphospholipid antibodies; APS, antiphospholipid syndrome; aβ2GPI, anti-β2 glycoprotein-I antibody; LA, lupus anticoagulant.;